Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02872155
Other study ID # NICIR
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date July 4, 2017
Est. completion date July 15, 2019

Study information

Verified date January 2021
Source Hospital Clinic of Barcelona
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates if oral hydratation is as effective as endovenous hydratation in the prophylaxis of contrast-induced nephropathy in patients renal insufficiency grade III under study conducting contrasted computed tomography.


Recruitment information / eligibility

Status Completed
Enrollment 264
Est. completion date July 15, 2019
Est. primary completion date July 15, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients of both sexes over 18 years - Candidates for a study with computed tomography and intravenous contrast - A glomerular filtration rate between 30 and 45 mL / min including both determinations - They have signed the written informed consent after being informed of the objectives and the nature of the case or be unable to have the authorization or agreement of its Exclusion Criteria: - refuse to participate in the study - pregnancy or lactation - Other risk factors for Contrast Induced Nephropathy: diabetes mellitus type I, have an age of 75 years or above, heart failure (defined by a scale New York Heart Association 3 or 4), hypotension (defined as systolic blood pressure <100), being treated with nephrotoxic medications. - Any disease or a history that, in the investigator's opinion, could confound the results of the study or pose an additional risk to patient treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Oral hydratation
500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
Drug:
Bicarbonate endovenous hydratation
Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.
Saline endovenous hydratation
If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.

Locations

Country Name City State
Spain Hospital Clínic i Provincial de Barcelona Barcelona

Sponsors (2)

Lead Sponsor Collaborator
David Garcia Cinca Fundacion Clinic per a la Recerca Biomédica

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of contrast induced nephropathy Contrast induced nephropathy defined as a creatinine increase> 0.5 mg
/ dl comparing the initial blood test to the blood test performed after 48-72 hours to the completion of the computed tomography
48-72 hours after the completion of the computed tomography
Secondary Need for hemodialysis Need for hemodialysis for one month after completion of the computed tomography, among patients who have undergone oral or intravenous hydration 15 days
Secondary Reversibility of contrast induced nephropathy Defined as no increase in creatinine> 0.5 mg / dl compared to the initial analysis performed 15 days
Secondary Proportion of adverse events Presence of adverse events, grade 3 adverse events and serious adverse events related to the investigational products during the study follow-up 15 days
See also
  Status Clinical Trial Phase
Completed NCT05990660 - Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery N/A
Recruiting NCT04096547 - Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
Completed NCT04024332 - Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects Phase 1
Completed NCT02849964 - Factors Related to Geographical Variation in the Incidence of End-stage Renal Failure: An Analysis in 5 French Regions N/A
Active, not recruiting NCT03672110 - Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen Phase 3
Completed NCT01462136 - PK Study of ACHN-490 Injection in Renally Impaired Subjects Phase 1
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT01172431 - Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency Phase 4
Completed NCT01545531 - Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance N/A
Completed NCT00770081 - Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study) Phase 3
Completed NCT00765830 - Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension) Phase 3
Terminated NCT00338455 - Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC Phase 2
Completed NCT00159614 - Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment Phase 2
Completed NCT02894385 - Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201) Phase 1
Completed NCT02894905 - A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335 Phase 1
Active, not recruiting NCT04876963 - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT03235375 - A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects Phase 1
Withdrawn NCT03329612 - Remote Ischemic Preconditioning in ACS Patients N/A
Recruiting NCT02578784 - DEB-after-Cutting Balloon-PTA in Dialysis Fistula Stenosis N/A